Bausch Health Announces Quebec Provincial Listing Of Prokedi For Treatment Of Schizophrenia In Adults

PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults. According to the Canadian product monograph, PrOKEDI® achieves clinically relevant concentrations of the active ingredient within the first few hours after injection, without the need for a loading dose or oral supplementation. It provides sustained release over a 4-week dosing interval, without the need for oral supplementation or a loading dose.1

This decision marks an important milestone in securing reimbursement for PrOKEDI® in Quebec. This listing follows negotiations concluded earlier this year with the Pan-Canadian Pharmaceutical Alliance (APP). Bausch Health will continue its efforts with other provincial jurisdictions in accordance with their respective reimbursement processes.